Latest News Releases Keyword Search Year All2026202520242023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996 3/17/26 Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer 3/10/26 Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum 2/24/26 Neurocrine Biosciences to Present at Upcoming Investor Conferences in March 2/11/26 Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026 1/26/26 Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia 1/21/26 Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results Resources Email Alerts 2025 Annual Report 2026 Proxy Statement Webcasts & Presentations
2/11/26 Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026
1/26/26 Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia
1/21/26 Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results